近日，ISCT（國(guó)際細(xì)胞治療協(xié)會(huì)）和 ICCBBA（國(guó)際血庫(kù)自動(dòng)化通用委員會(huì)）在 Elsevier旗下期刊《Cytotherapy》上發(fā)布了不同組織來(lái)源的間充質(zhì)干細(xì)胞縮寫(xiě)命名的統(tǒng)一標(biāo)準(zhǔn)。
The Cellular Therapy Coding and Labeling Advisory Group of the International Council for Commonality in Blood Banking Automation and the International Society for Cell & Gene Therapy mesenchymal stromal cell (MSC) committee are providing specific recommendations on abbreviating tissue sources of culture-adapted MSCs. These recommendations include using abbreviations d on the ISBT 128 terminology model that specifies standard class names to distinguish cell types and tissue sources for culture-adapted MSCs. Thus, MSCs from bone marrow are MSC(M), MSCs from cord blood are MSC(CB), MSCs from adipose tissue are MSC(AT) and MSCs from Wharton's jelly are MSC(WJ). Additional recommendations include using these abbreviations through the full spectrum of pre-clinical, translational and clinical research for the development of culture-adapted MSC products. This does not apply to basic research focused on investigating the developmental origins, identity or functionalities of endogenous progenitor cells in different tissues. These recommendations will serve to harmonize nomenclature in describing research and development surrounding culture-adapted MSCs, many of which are destined for clinical and/or commercial translation. These recommendations will also serve to align research and development efforts on culture-adapted MSCs with other cell therapy products.
根據(jù)ISBT（國(guó)際輸血協(xié)會(huì)）的128項(xiàng)術(shù)語(yǔ)模型 （該模型針對(duì)標(biāo)準(zhǔn)分類）進(jìn)行命名以區(qū)分所培養(yǎng)的間充質(zhì)干細(xì)胞不同組織來(lái)源的細(xì)胞類型：骨髓間充質(zhì)干細(xì)胞是MSC(M)；臍帶血間充質(zhì)干細(xì)胞是MSC(CB)；脂肪組織間充質(zhì)干細(xì)胞是MSC(AT)；臍帶間充質(zhì)干細(xì)胞是MSC(WJ)。
我們簡(jiǎn)單回顧一下， （ISCT）定義的間充質(zhì)干細(xì)胞（MSC）的標(biāo)準(zhǔn)，包括：（1）貼壁細(xì)胞，（2）多系分化能力，可在體外分化成成骨細(xì)胞（Osteoblast）、脂肪細(xì)胞（adipocyte）、軟骨細(xì)胞（chondrocyte)、肌細(xì)胞（myocyte）和其它結(jié)締組織，（3）具有關(guān)鍵表面標(biāo)志分子，包括：CD29、CD44、CD73、CD105和CD146，并且不具有如下的造血細(xì)胞表面標(biāo)志分子：CD34、CD45、CD14、CD11b，CD79α，CD19和HLA-DR。
ISCT介紹：
ISCT成立于1992年，是一個(gè)由臨床醫(yī)生、監(jiān)管機(jī)構(gòu)、研究人員、技術(shù)人員和行業(yè)合作伙伴組成的全球性非盈利組織。目前，ISCT由來(lái)自60多個(gè)國(guó)家、5個(gè)地理區(qū)域的2400多名細(xì)胞治療專家組成。
ISCT是專注于開(kāi)發(fā)基于細(xì)胞療法的臨床前和轉(zhuǎn)化方面的全球領(lǐng)導(dǎo)者，推動(dòng)了科學(xué)研究向患者創(chuàng)新療法的發(fā)展。ISCT提供了一個(gè)獨(dú)特的協(xié)作環(huán)境，可解決轉(zhuǎn)化的三個(gè)關(guān)鍵領(lǐng)域：學(xué)術(shù)，監(jiān)管和商業(yè)化。通過(guò)與全球監(jiān)管機(jī)構(gòu)，學(xué)術(shù)機(jī)構(gòu)和行業(yè)合作伙伴的牢固關(guān)系，ISCT引領(lǐng)了護(hù)理標(biāo)準(zhǔn)研究的發(fā)展。ISCT成員擁有一個(gè)共同的愿景，將細(xì)胞和基因療法轉(zhuǎn)化為安全有效的療法，以改善全世界患者的生活。
▎文源：https://www.isctglobal.org；
美賽爾內(nèi)容團(tuán)隊(duì)編輯。
